Kiniksa names Ross Moat president and chief operating officer
The board compensation committee acted October 17, 2026, with Moat's pay set to rise in 2027 and no change to his reporting line.
Kiniksa Pharmaceuticals International, plc disclosed in an 8-K that on October 17, 2026, the Compensation Committee of its Board of Directors appointed Ross Moat as President and Chief Operating Officer, effective immediately.1
Moat's reporting structure stays the same. He will continue to report to Sanj K. Patel, the Company's Chairman and Chief Executive Officer.1
The filing also outlines a future pay increase. Effective January 1, 2027, the Committee approved increases in Moat's annual base salary and annual target bonus to $700,000 and 60% from $650,000 and 55%, respectively.1
Moat is not new to the company. He has served in varying capacities at Kiniksa since June 2019, most recently as the company's EVP, Chief Operating Officer.1 In that prior role, he oversaw the company's commercial, clinical, regulatory and manufacturing operations.1 Further background on him is available elsewhere. His full biographical information is disclosed in the company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 16, 2026.1
The filing notes two standard disclosures tied to the appointment. There are no family relationships between Moat and any director or executive officer of the company, and there are no related party transactions involving Moat and the company requiring disclosure under Item 404(a) of Regulation S-K.1
The 8-K was signed on October 22, 2026, by Douglas Barry, the company's Senior Vice President and Chief Legal Officer.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.